<DOC>
	<DOCNO>NCT03019991</DOCNO>
	<brief_summary>The purpose study evaluate Pharmacokinetics Danoprevir single dose ( 100mg QD day 1 , day 4 day 14 ) Ritonavir-boosted Danoprevir ( 100mg QD day 4 day 14 ) single multiple dos ( 100mg BID day 5 -day 13 ) healthy volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Danoprevir/r Healthy Volunteers China</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing able provide write informed consent Healthy men woman base history , physical examination , laboratory examination ECG . Negative serum urine pregnancy test result ( sensitivity 25 mIU well ) woman childbearing potential within 24hour period first dose study drug Female patient childbearing potential ( menopause within 1 year ) must agree use two reliable form effective nonhormonal contraception ( i.e. , condom , cervical barrier , intrauterine device , spermicide , sponge ) , least 1 must physical barrier method , treatment least 6 month follow last dose ribavirin All male patient female partner childbearing potential must use two reliable form effective contraception ( combine ) treatment 6 month follow last dose ribavirin Others specify detail protocol Have medical history , disease , cardiovascular system , respiratory system , endocrine metabolic system , urinary system , digestive system , blood system , nerve system disease psychiatric disease acute chronic infectious disease malignant tumor . Has history drug food allergy . Positive hepatitis A antibody，positive hepatitis B surface antigen， positive hepatitis C antibody，syphilis antibody HIV antibody screen . Had gastrointestinal surgery , vagotomy , intestinal resection possible interference gastrointestinal peristalsis , pH absorb surgery . Pregnant , lactate menstrual period unwilling reliable contraception period woman childbearing age . Female partner fertility reliable contraceptive measure men .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacokinetics , Danoprevir</keyword>
</DOC>